HOUSTON, May 27, 2021 – Vivante Health, the leader in digital medicine for digestive health and disease, proudly announced that Bruce E Sands, MD, MS and Mark Pimentel, MD have joined the company’s Scientific Advisory Board. Both Dr. Sands and Dr. Pimentel are leaders in their respective fields of Gastroenterology, and will be integral in shaping Vivante’s roadmap for research and innovation. Chief Medical Officer at Vivante Health, Simon C. Mathews, MD, commented “We are incredibly fortunate to have two giants in the field of Gastroenterology provide their guidance and wisdom in advancing patient outcomes and experience through digital health.”Bill Snyder, CEO of Vivante Health says, “We are thrilled to welcome Dr. Sands and Dr. Pimentel to our clinical advisory board as we continue our work to improve the digestive health of people across the country.”
Bruce Sands, MD, MS is the Dr. Burrill B. Crohn Professor of Medicine (Gastroenterology) at the Icahn School of Medicine at Mount Sinai and Chief of the Division of Gastroenterology for the Mount Sinai Health System. Dr. Sands is an expert in the management of inflammatory bowel diseases (IBD) and has earned an international reputation for his care of patients with complex and refractory disease. He is widely recognized for his innovative treatment of IBD and for his clinical investigations of new therapeutics. He was among the first to report the efficacy of infliximab-a drug used to treat autoimmune diseases-in ulcerative colitis, a result later confirmed in large, multi-center randomized controlled trials. Vivante is thrilled to have his expertise as a part of its Scientific Advisory Board. More information about Dr. Sands can be found here.
Mark Pimentel, MD, is Associate Professor of Medicine and Gastroenterology, and Executive Director of the Medically Associated Science and Technology (MAST) program at Cedars-Sinai. Dr. Pimentel is a leading expert in developing diagnostic and therapeutic programs for small intestinal bacterial overgrowth (SIBO), Irritable Bowel Syndrome (IBS), and other diseases linked to the microbiome. Dr. Pimentel is credited for developing the first blood test for IBS, discovering rifaximin for the treatment of IBS-D, identifying the auto-immune basis for IBS/SIBO, and developing the first multi-gas breath test for SIBO. Vivante is thrilled to have his expertise as a part of its Scientific Advisory Board. More information about Dr. Pimentel can be found here.
About Vivante Health
Vivante Health is an innovative digital healthcare company reinventing the way chronic conditions are managed, gut first. Our all-in-one gut health program, GIThrive, empowers people—through brilliant technology, advanced science, and on-demand human support—to improve digestive health, while lowering their cost of care. Click here to learn how employers and health plans are saving money with GIThrive or email [email protected]
